Company signals · Biotech & Pharma
BioDuro
1 signal in the current window, with MitchelLake's leadership read on each.
Market context: Against a Talent Market Index of 98.6 (Neutral) (down 1.4 month-on-month), Americas is at easing (-2.6pts) on signal share.
BioDuro: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 19 tracked companies; 0.1% of MitchelLake's Americas signal flow.
Signals at BioDuro
More signals across Biotech & Pharma
Partnership · Americas
Ratio Therapeutics →Ratio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Partnership · Americas
Bristol Myers Squibb →Bristol Myers Squibb entered into a major alliance with Chinese pharmaceutical firm Hengrui involving up to 13 drugs and valued at up to $15.2 billion. This represents significant international collaboration in drug development and commercialization.
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Intelligence powered by Autonodal ↗